Beclomethasone/Formoterol in Extra-Fine Formulation Improves Small Airway Dysfunction in COPD Patients.

ABSTRACT:

Introduction

In patients with chronic obstructive pulmonary disease (COPD), small airway dysfunction (SAD) is a key element and a functional consequence of the pathology. The exact role of SAD as a specific 'pharmacological target' represents an important research topic. Our objective was to ascertain whether an extra-fine formulation of beclomethasone dipropionate/formoterol fumarate (BDP/FF) NEXThaler^® 100/6 μg b.i.d. could improve SAD and, consequently, the quality of life of COPD patients.

Methods

We enrolled COPD patients with severe airflow obstruction and at least one moderate exacerbation in the previous year, having started treatment with BDP/FF NEXThaler^® for no more than 1 week. Patients underwent three visits: at the start of the treatment (

SUBMITTER: Pisi R 

PROVIDER: S-EPMC8137789 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature